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I. Abstract

•

Canonical functions of E2F1 (E2 promoter
binding factor) are involved in transcription of
genes and regulation of many cellular
processes. Its involvement with RB
(Retinoblastoma) can either promote or repress
genes important for cell cycle progression
depending on the activity of RB. In response to
DNA damage E2F1 promotes DNA repair
through its essential post-translational
modifications including phosphorylation and
acetylation. Reports on E2F1 methylation
suggests that it also undergoes symmetric and
asymmetric dimethylation at different arginine
residues (SDMA and ADMA) during normal
proliferation and genotoxic conditions. We are
currently exploring the potential SDMA and
ADMA sites of E2F1, their readers, and their
biological functions. Recent work from our group
found that SART3 (Squamous cell carcinoma
antigen recognized by T-cells 3), is a new class
of readers of SDMA. Here we study the
interaction between SART3 and E2F1. Our
experiments used GFP-Trap
immunoprecipitation (IP) assay in cells
overexpressing EGFP-fused SART3 wild type
(WT) or aromatic residue mutants. Then we
treated the WT cells with PRMT5 inhibitor
(PRMT5i) to know if the interaction is dependent
on methylation. Our preliminary data suggests
that SART3 interacts with E2F1; and this
interaction requires both aromatic residues of
SART3 and symmetric arginine dimethylation.
Thus, SART3 is likely a novel reader of
methylated E2F1.

•

II. Background
E2F1 – A Transcription Factor with Pleiotropic
Functions
• E2F1 protein belongs to E2F family of
transcription factors.
• E2F1 regulates the expression of genes
involved in cell proliferation, apoptosis, DNA
repair and other cellular processes.
• E2F1 activity is negatively regulated by RB
tumor suppressor.

SART3 is a cancer prognostic marker; increased
SART3 levels decreases survival in liver cancer
and melanoma.
SART3 lacks a Tudor domain but has aromatic
residues which may act as a methyl reader.

V. Results
Probing SART3-E2F1 interaction in cells
overexpressing SART3 WT and mutants

Figure 8. Interaction of E2F1 with SART3 is dependent
on its symmetric dimethylation (SDM). U2OS cells
were transfected with EGFP fused SART3 WT plasmid at
indicated concentration. 8h post-transfection cells were
either treated with DMSO or EPZ015666 (PRMT5 inhibitor
– 5 μM) for 48h. Lysates were subjected to GFP-Trap IP
for 3h, followed by blotting with indicated antibodies (left
panel). Input controls are on the right.

Figure 2. Domain structure of SART3. SART3 has Nterminal and C-Terminal half-a-tetracopeptide repeats
(HATs). La - Linker helix. Created in BioRender.com

Figure 5. Microscopic image of cells overexpressing
EGFP-fusion proteins. U2OS cells were transfected with
2.5 μg of either EGFP or EGFP-fused with SART3 WT or
mutant plasmids, then imaged 48h post-transfection.

Figure 3. Structural modeling identified an aromatic
groove between the two blocks of HAT repeats.
Mutational analysis revealed that the 4 aromatic residues
highlighted in “pink” are critical for a SART3 interaction
with a methylated peptide.

Figure 9. SART3 interaction with E2F1 after 48-hour
inhibitor treatment of PRMT5 and PRMT1. U2OS cells
were treated with the indicated PRMT inhibitors for 48h.
Lysates were subjected to GFP-Trap IP for 3h, followed
by blotting with indicated antibodies (left panel). Input
controls are on the right. Coilin is used as a positive
control.
Like figure 6, RB shows a higher molecular weight in the
IP panel (left) compared to its input (right).

III. Objective
•
•

To determine whether SART3 interacts with
E2F1; and is dependent on its aromatic
residues.
To determine whether SART3 – E2F1
interaction requires symmetric dimethylation
(SDM) of E2F1.

IV. Methods
Probing SART3-E2F1 interaction by GFP-Trap
immunoprecipitation

Figure 6. SART3 interacts with E2F1, and it is affected
by mutations in its aromatic cage. U2OS cells were
treated with the same procedure as in figure 5. Lysates
were subjected to GFP-Trap IP for 3h, followed by blotting
with indicated antibodies (left panel). Input controls are on
the right. Coilin is used as a positive control.
RB shows higher molecular weight band (bottom left
panel) in GFP-Trap IP blot as compared to input control
(bottom right panel). This interaction needs to be further
validated by RB knockdown experiments.

Probing SART3-E2F1 interaction in presence of
PRMT inhibitors

VI. Conclusions
•
•

•

•
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Figure 1. Regulation of E2F1 function. RB is
hyperphosphorylated and inactivated by CDK2 during cell
cycle progression, thus E2F1 can recruit histone
acetyltransferases to activate transcription.

SART3 – Novel Reader of Arginine
Methylation?
SART3 is an RNA-binding nuclear protein and
regulates gene expression by assisting in premRNA splicing.

GFP

(Adapted from ChromoTek website)

Figure 4. Comparison of IP using GFP-Trap nanobody
and anti-GFP antibody. The GFP-Fusion proteins used
in this study are listed above.

SART3 interacts with E2F1 through a
potential aromatic groove in SART3.
The SART3-E2F1 interaction is dependent
on PRMT5 activity, suggesting SART3
may read a symmetric methylation site on
E2F1.
The association of SART3 with E2F1 may
regulate E2F1-dependent activities in
transcription and/or DNA repair.
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